argenx announces positive topline results from Phase 2 FB102 study
argenx (ARGX) announced positive topline results from a Phase 2 study of FB102 in celiac disease.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
argenx (ARGX) announced positive topline results from a Phase 2 study of FB102 in celiac disease.